Literature DB >> 25295834

Economic evaluation of a randomized controlled trial of pharmacist-supervized patient self-testing of warfarin therapy.

J Gallagher1, S Mc Carthy, N Woods, F Ryan, S O' Shea, S Byrne.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: The increase in numbers of patients requiring oral anti-coagulation testing in outpatient clinics has focused attention on alternative flexible systems of anti-coagulation management. One option is pharmacist led patient self-testing (PST) of international normalised ratio (INR) levels. PST has demonstrated improvements in anti-coagulation control, but its cost-effectiveness is inconclusive. This study reports the first cost-effectiveness evaluation of a randomized controlled trial of an automated direct-to-patient expert system, enabling remote and effective management of patients on oral anti-coagulation therapy.
METHODS: We conducted an economic evaluation alongside a randomised controlled trial investigating a pharmacist led PST method. The primary outcome was to determine the cost effectiveness of PST in comparison with usual care (management in a hospital based anti-coagulation clinic). Long term anti-coagulation patients were recruited to a 6 month cross over study between PST and routine care in an anti-coagulation clinic. Economic evaluation was from the healthcare payer perspective. RESULTS AND DISCUSSION: On a per patient basis over a 6 month period, PST resulted in an incremental cost of €59.08 in comparison with routine care. Patients achieved a significantly higher time in therapeutic range (TTR) during the PST arm in comparison with routine care, (72 ± 19.7% vs. 59 ± 13.5%). Overall cost of managing a patient through pharmacist supervised PST for a 6 month period is €226.45. Additional analysis of strategies from a societal perspective indicated that PST was the dominant strategy. WHAT IS NEW AND
CONCLUSION: Pharmacist led patient self-testing is a viable method of management. It provides significant increases in anti-coagulation control for a minimal increase in cost.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  anti-coagulation; clinical pharmacy; cost-effectiveness; international normalised ratio; pharmaceutical care; pharmacoeconomics; pharmacy practice; warfarin

Mesh:

Substances:

Year:  2014        PMID: 25295834     DOI: 10.1111/jcpt.12215

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  5 in total

1.  Pharmacist's interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial.

Authors:  Slaven Falamić; Marko Lucijanić; Maja Ortner Hadžiabdić; Srećko Marušić; Vesna Bačić Vrca
Journal:  Int J Clin Pharm       Date:  2018-07-26

Review 2.  Self-monitoring and self-management of oral anticoagulation.

Authors:  Carl J Heneghan; Josep M Garcia-Alamino; Elizabeth A Spencer; Alison M Ward; Rafael Perera; Clare Bankhead; Pablo Alonso-Coello; David Fitzmaurice; Kamal R Mahtani; Igho J Onakpoya
Journal:  Cochrane Database Syst Rev       Date:  2016-07-05

3.  Home management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR.

Authors:  Sabrina da Silva Saraiva; Fernanda Andrade Orsi; Marcos Pereira Santos; Tania Machado; Silmara Montalvão; Carolina Costa-Lima; Erich Vinícius de Paula; Marina Pereira Colella; Joyce Annichino-Bizzacchi
Journal:  J Thromb Thrombolysis       Date:  2016-07       Impact factor: 2.300

4.  Impact of a pharmaceutical care programme for patients with chronic disease initiated at the emergency department on drug-related negative outcomes: a randomised controlled trial.

Authors:  Ana Juanes; Noe Garin; Maria Antonia Mangues; Sergio Herrera; Mireia Puig; Maria Jose Faus; Maria Isabel Baena
Journal:  Eur J Hosp Pharm       Date:  2017-02-23

5.  Optimizing Prophylactic Antibiotic Practice for Cardiothoracic Surgery by Pharmacists' Effects.

Authors:  Ling Zhou; Jingjing Ma; Jie Gao; Shiqi Chen; Jianan Bao
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.